https://www.epo.org/fr/boards-of-appeal/decisions/t192735eu1
T 2735/19 (TAS-102 administration/TAIHO) du 19.07.2023
tas 102273519administrationtaiho
https://www.prnewswire.com/news-releases/taihos-tas-102-meets-primary-endpoint-of-improving-overall-survival-in-phase-iii-terra-study-in-asian-patients-with-refractory-metastatic-colorectal-cancer-300244624.html
Taiho's TAS-102 Meets Primary Endpoint of Improving Overall Survival in Phase III TERRA Study in...
/PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. of Tokyo announced on April 1 results from its Phase III TERRA study on its oral combination anticancer drug...
https://www.prnewswire.com/sv/pressmeddelanden/taiho-oncologys-tas-102-meets-primary-endpoint-of-improving-overall-survival-in-global-phase-iii-recourse-trial-in-refractory-metastatic-colorectal-cancer-258860441.html
Taiho Oncology's TAS-102 Meets Primary Endpoint of Improving Overall Survival in Global Phase III...
/PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan) and its division Taiho Oncology, Inc. (Princeton, N.J.) announced on May 12 results from its...
https://www.mayo.edu/research/clinical-trials/cls-20366146?&p=1
TAS-102 And Radiation Therapy In Treating Patients With Rectal Cancer That Is Locally Recurrent,...